Jefferies cuts Lanxess stock price target on cost pressures

Jefferies cut Lanxess's price target to €11 from €14 and retained its Underperform rating, while reducing EBITDA estimates by an average 2%. It forecasts Q3 EBITDA of €134 million, 3% below the €139 million consensus, citing higher European gas costs, depressed utilization rates and weakening demand. Jefferies also projects FY2026 EBITDA of €482 million, 4% below the midpoint of company guidance and 3% below consensus, with Chinese competition, weak construction demand and Saltigo losses remaining key headwinds.

Analysis

The key equity risk is not a modest quarterly EBITDA miss but a prolonged under-absorption cycle: low plant utilization converts relatively small volume or energy-cost disappointments into disproportionate EBITDA and free-cash-flow pressure. A recovery valuation for LXS is therefore premature until management demonstrates sequential improvement in volumes and utilization, rather than merely holding annual guidance. The expected earnings rebound also leaves little room for further restructuring charges, working-capital outflows, or delayed cash proceeds from portfolio actions.

Competitive pressure is most acute in commodity-adjacent intermediates, where Chinese overcapacity can keep European pricing below cash-cost recovery for longer than investors expect. BASF (BAS:GR), Evonik (EVK:GR), Clariant (CLN:SW), and Arkema (AKE:FP) share European energy and industrial-demand exposure, but diversified companies with larger downstream formulation or regional footprints should weather the cycle better than LXS. A second-order loser is European construction-linked chemical demand: a weaker industrial recovery would defer operating leverage across pigments, coatings inputs, and additives.

Near term, the stock may be technically vulnerable around earnings if consensus has not fully reset, but the larger 6-18 month issue is whether European chemical capacity rationalization occurs before Chinese supply discipline improves. The contrarian upside case is substantial only if gas prices retreat materially and management delivers credible asset-sale cash realization earlier than the market assumes; absent those conditions, a low absolute share price is not evidence of a valuation floor. Jefferies' estimate change is a weak standalone catalyst, so conviction should be driven by sector volume data, energy spreads, and revised company guidance rather than the target-price action itself.

Key Decisions for Investors

• Maintain an underweight/short bias in LXS:GR into the next results cycle only if consensus EBITDA remains above management's implied run-rate; target a 10-15% downside on a guidance reset, with a stop if quarterly EBITDA exceeds consensus and management raises full-year guidance.
• Express relative European chemical weakness through long BAS:GR / short LXS:GR over 3-6 months. BASF is not immune to European gas costs, but its scale, diversification, and restructuring capacity provide better downside resilience; reassess if LXS demonstrates two consecutive quarters of volume-led margin expansion.
• Avoid using LNXSF OTC shares for tactical positioning because liquidity and execution can distort returns; use the Frankfurt-listed LXS line or listed European chemical sector proxies where mandate permits.
• Set alerts on European natural-gas forward prices and China chemical-export pricing: a sustained 20%+ decline in European gas forwards or evidence of Chinese capacity curtailments would weaken the short thesis before reported earnings improve.
• No actionable position in JEF from this item; the research note itself has immaterial earnings relevance unless it signals a broader, independently corroborated downgrade cycle across European chemicals.